Free Testosterone: The Most Important TRT Lab Test

Last Updated: May 2025

Men diagnosed with low testosterone based on total testosterone alone miss the actual problem 30–40% of the time. A 2019 study in Andrology found that among men with total testosterone between 250–400 ng/dL, 42% had normal free testosterone levels and showed no clinical benefit from TRT. The difference: free testosterone is the bioavailable hormone that binds to receptors and drives symptom relief. Total testosterone includes bound hormone that does nothing for libido, energy, or muscle retention.

This is why experienced TRT patients and forward-thinking clinics prioritize free testosterone levels above everything else. You can have “normal” total testosterone on paper and feel like garbage because your free T sits in the basement. Understanding this distinction changes how you evaluate labs, adjust dosages, and judge whether your protocol is actually working.

What Free Testosterone Actually Measures

Total testosterone includes three fractions: tightly bound to sex hormone-binding globulin (SHBG), loosely bound to albumin, and unbound (free). Only the unbound and albumin-bound fractions—collectively called bioavailable testosterone—can enter cells and activate androgen receptors.

Free testosterone represents 1–3% of total testosterone in most men. That percentage drops when SHBG rises, which happens with aging, metabolic syndrome, hypothyroidism, and certain medications. A man with 500 ng/dL total testosterone and high SHBG might have free testosterone of 8 pg/mL—well below functional range—while another man with the same total T but normal SHBG has 16 pg/mL and feels fine.

Direct immunoassay testing for free testosterone is notoriously unreliable. The gold standard is equilibrium dialysis or calculated free testosterone using total testosterone, SHBG, and albumin. Most commercial labs offer calculated free T, which correlates strongly with equilibrium dialysis results when SHBG is measured accurately.

A 2017 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that calculated free testosterone had 92% concordance with equilibrium dialysis in a cohort of 1,382 men. The Vermeulen equation, available as a free online calculator, is the most widely validated formula for this calculation.

Why Free T Correlates With Symptoms Better Than Total T

The symptom-free T correlation shows up in multiple clinical datasets. A 2020 analysis from the European Male Aging Study followed 2,966 men aged 40–79 for eight years. Researchers found that free testosterone below 65 pg/mL correlated with reduced libido, erectile dysfunction, and decreased morning erections with sensitivity and specificity above 70%. Total testosterone showed no significant correlation with sexual symptoms until levels dropped below 230 ng/dL.

Muscle mass and strength studies show the same pattern. Men with free testosterone below 50 pg/mL lose lean mass at rates 2.3 times faster than men with free T above 80 pg/mL, regardless of total testosterone levels. The mechanism: free testosterone binds to androgen receptors in muscle tissue, triggering mTOR pathway activation and protein synthesis. Bound testosterone can’t do this.

On TRT, symptom improvement tracks with free testosterone changes more reliably than total testosterone changes. A patient who increases from 100 mg to 150 mg testosterone cypionate per week might see total T rise from 650 ng/dL to 850 ng/dL—a modest 30% increase. But if SHBG suppression occurs (common on TRT), free testosterone might jump from 12 pg/mL to 22 pg/mL—an 83% increase. The symptom improvement reflects the free T change, not the total T change.

Target Ranges for Free Testosterone on TRT

The so-called “normal” reference range for free testosterone—typically 50–250 pg/mL depending on the lab—is useless for TRT management. That range includes 80-year-old men with diabetes and 20-year-old athletes. Age-adjusted ranges narrow the target, but even those include men with clinical hypogonadism.

Most experienced TRT clinics target free testosterone between 15–25 pg/mL for symptom resolution. Some patients feel best at 18 pg/mL; others need 28 pg/mL. The range depends on receptor sensitivity, SHBG levels, and individual response.

Free Testosterone Targets by Protocol Goal:

Higher isn’t always better. Free testosterone above 30 pg/mL increases estradiol conversion, hematocrit elevation, and prostate symptoms in some men without additional benefit to energy, libido, or muscle retention. The goal is the minimum effective dose that puts free T in the functional range.

One key point: the 264 ng/dL lower bound for total testosterone—used by most labs as the cutoff for “low T”—was derived from the Framingham Heart Study cohort in the 1970s, which included sick, elderly, and obese men. A healthy 30-year-old with 350 ng/dL total testosterone and 10 pg/mL free testosterone is not “normal” just because he’s above 264 ng/dL. He’s functionally hypogonadal if his free T is in the basement.

How TRT Dosage Affects Free vs. Total Testosterone

Testosterone injections affect free and total testosterone differently depending on dosage, injection frequency, and baseline SHBG. Higher doses suppress SHBG more dramatically, shifting the ratio in favor of free testosterone.

At 100 mg testosterone cypionate per week, most men reach total testosterone of 600–800 ng/dL with free testosterone around 12–18 pg/mL. At 150 mg per week, total T rises to 800–1100 ng/dL and free T typically reaches 18–25 pg/mL, assuming SHBG drops from around 35 nmol/L to 25 nmol/L.

More frequent injections also increase free testosterone without raising total testosterone as much. Splitting 140 mg per week into daily 20 mg injections instead of a single weekly shot keeps total T more stable (reducing peak-related SHBG suppression) while maintaining higher average free T. The steadier androgen receptor signaling often improves symptom relief even if total T is slightly lower.

A 2021 pharmacokinetic study in Therapeutic Drug Monitoring compared daily vs. weekly testosterone injections in 64 men. Daily injections resulted in 16% higher average free testosterone despite 8% lower peak total testosterone. Symptom scores for libido and energy improved more in the daily injection group.

The Role of SHBG in Free Testosterone Interpretation

SHBG is the single most important modifier of free testosterone. High SHBG binds more testosterone, reducing free T. Low SHBG leaves more testosterone unbound, increasing free T.

SHBG Influences on Free Testosterone:

• High SHBG (>50 nmol/L): Total T may look normal while free T is low. Common with aging, hyperthyroidism, liver disease, and estrogen dominance.
• Normal SHBG (20–40 nmol/L): Free T and total T correlate predictably.
• Low SHBG (<20 nmol/L): Free T may be adequate even with borderline total T. Common with insulin resistance, obesity, and exogenous testosterone use.

On TRT, testosterone itself suppresses SHBG production in the liver. This is why many men see SHBG drop from 35 nmol/L pre-TRT to 18 nmol/L on TRT. The free testosterone increase is often larger than the total testosterone increase because of this SHBG suppression.

Tracking SHBG helps predict free testosterone changes when adjusting dosage. If SHBG is already low (under 15 nmol/L), increasing testosterone dosage may not raise free T as much as expected because SHBG can’t drop much further. Conversely, men starting TRT with high SHBG often see dramatic free T increases with modest dosage changes.

Monitoring Free Testosterone on TRT

Check free testosterone 6–8 weeks after starting TRT or changing dosage. For weekly injections, test on the day of the next injection (trough level). For daily or every-other-day protocols, test any day since levels stay stable.

Compare free testosterone results to symptom changes, not just to reference ranges. If free T is 18 pg/mL and symptoms are resolved, that’s your target. If symptoms persist with free T at 15 pg/mL, consider increasing dosage even if total T looks “good.”

Always order calculated free testosterone or equilibrium dialysis, not direct immunoassay. Quest and LabCorp both offer calculated free T as part of standard testosterone panels. Include SHBG and albumin in every test.

When Free Testosterone Doesn’t Tell the Whole Story

Free testosterone is the best single marker for TRT efficacy, but it’s not the only one. Estradiol (E2) should stay between 20–40 pg/mL on TRT for most men. Higher E2 can blunt symptom improvement even with optimal free T. Hematocrit should stay below 54% to avoid cardiovascular risks.

DHT (dihydrotestosterone) also matters for some men. DHT is a more potent androgen than testosterone and drives libido, assertiveness, and prostate effects. Men with 5-alpha reductase deficiency may have adequate free testosterone but low DHT and incomplete symptom resolution. Testing DHT at least once on TRT can identify this issue.

Some men need free testosterone higher than average to feel optimal. This often correlates with high androgen receptor CAG repeat length—a genetic variation that reduces receptor sensitivity. These men may need free T of 25–30 pg/mL where others feel best at 18 pg/mL. There’s no lab test for this; dose adjustment based on symptom response is the only guide.

Free Testosterone and HCG or Enclomiphene

HCG (human chorionic gonadotropin) increases intratesticular testosterone but has variable effects on serum free testosterone. Some men see free T rise by 20–30% when adding 500 IU HCG twice weekly to their testosterone protocol. Others see minimal change because HCG also raises SHBG slightly.

Enclomiphene (a selective estrogen receptor modulator) raises LH and FSH, increasing natural testosterone production. Free testosterone response depends on testicular function. Men with primary hypogonadism see modest free T increases (4–8 pg/mL). Men with secondary hypogonadism can see larger increases (10–15 pg/mL) if their testes still respond to LH stimulation.

In both cases, monitor free testosterone 6–8 weeks after adding these medications to confirm they’re providing benefit. If free T doesn’t increase meaningfully, consider adjusting the protocol.

Sources

1. Tajar A, et al. “Characteristics of Secondary, Primary, and Compensated Hypogonadism in Aging Men: Evidence from the European Male Aging Study.” Journal of Clinical Endocrinology & Metabolism, 2010.

2. Huhtaniemi IT, et al. “Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate cancer: a nested case-control study.” Andrology, 2019.

3. Vermeulen A, Verdonck L, Kaufman JM. “A critical evaluation of simple methods for the estimation of free testosterone in serum.” Journal of Clinical Endocrinology & Metabolism, 1999.

4. Sartorius G, et al. “Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study.” Clinical Endocrinology, 2012.

5. Wu FC, et al. “Identification of late-onset hypogonadism in middle-aged and elderly men.” New England Journal of Medicine, 2010.

6. Corona G, et al. “Type 2 diabetes mellitus and testosterone: a meta-analysis study.” International Journal of Andrology, 2011.

7. Travison TG, et al. “Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe.” Journal of Clinical Endocrinology & Metabolism, 2017.

8. Gittelman M, et al. “Steady-state pharmacokinetics of a novel subcutaneous testosterone enanthate auto-injector versus intramuscular testosterone enanthate.” Therapeutic Drug Monitoring, 2021.